SCHEMBL13734799

SCHEMBL13734799

O=C(O)NCCc1c[nH]cn1

nearest known ligand 0.33

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.33
RAB9A P51151 3/20 0.33
HTT P42858 2/20 0.33
GAA P10253 1/20 0.33
QPCT Q16769 1/20 0.33
QPCTL Q9NXS2 1/20 0.33
LTA4H P09960 2/20 0.32
PLA2G2A P14555 2/20 0.32
ATM Q13315 1/20 0.32
HPGD P15428 1/20 0.32
ALDH1A1 P00352 3/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
SMN1; SMN2 Q16637 3/20 0.31
NPC1 O15118 2/20 0.31
MTNR1A P48039 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7994725 0.90 L3MBTL1 (0.33) RAB9AGAAHPGDALDH1A1L3MBTL1
SCHEMBL17473831 0.87 MMP9 (0.35) MAPTRAB9AQPCTQPCTLALDH1A1
SCHEMBL21820172 0.87 CNR1 (0.36) QPCTQPCTLALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL4385039 0.87 TRPV1 (0.36) HPGDSMN1; SMN2KMT2A
SCHEMBL4382422 0.87 TRPV1 (0.36) HPGDSMN1; SMN2KMT2A
SCHEMBL17473828 0.86 ST14 (0.36) MAPTRAB9AHTTGAAQPCT
Oxalic Acid SCHEMBL31530509 0.85 HPGD (0.35) MAPTHTTGAAHPGDSMN1; SMN2
SCHEMBL5508626 0.84 NOTUM (0.38) RAB9AQPCTQPCTLALDH1A1L3MBTL1
SCHEMBL514228 0.84 QPCT (0.49) MAPTHTTQPCTQPCTLHPGD
SCHEMBL17473827 0.84 CYP3A4 (0.41) HPGDL3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116546988-A Prodrugs of 5α -hydroxy-6β - [2- (1H-imidazol-4-yl) ethylamino ] cholestan-3β -ol and pharmaceutical compositions for cancer treatment containing the same 登德罗杰尼克斯公司 2023-08-04 CN claimed
CN-113396153-A Amino acid salts of nicotinic acid mononucleotide and nicotinamide mononucleotide as anti-aging agents 江普斯塔特生育有限公司 2021-09-14 CN claimed
EP-2699557-B1 3-(OXAZOL-2-YL-ETHOXY)- AND 3-(THIAZOL-2-YL-ETHOXY)-BENZAMIDE DERIVATIVES AS ANTI-BACTERIAL AGENTS BIOTA SCIENT MANAGEMENT (AU) 2017-08-16 EP claimed
US-9511073-B2 Aromatic amides and uses thereof TAXIS PHARMACEUTICALS, INC. (US) 2016-12-06 US claimed
US-20140135332-A1 AROMATIC AMIDES AND USES THEREOF BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2014-05-15 US claimed
EP-2699557-A1 AROMATIC AMIDES AND USES THEREOF Biota Scientific Management Pty Ltd (AU) 2014-02-26 EP claimed
WO-2012142671-A1 AROMATIC AMIDES AND USES THEREOF BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) 2012-10-26 WO claimed
US-11945806-B2 Stabilization of amyloidogenic immunoglobulin light chains THE SCRIPPS RESEARCH INSTITUTE 2024-04-02 US disclosed
US-20230331737-A1 MTORC1 MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS, INC. 2023-10-19 US disclosed
CN-116546988-A Prodrugs of 5α -hydroxy-6β - [2- (1H-imidazol-4-yl) ethylamino ] cholestan-3β -ol and pharmaceutical compositions for cancer treatment containing the same 登德罗杰尼克斯公司 2023-08-04 CN disclosed
US-20220204485-A1 STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS THE SCRIPPS RESEARCH INSTITUTE 2022-06-30 US disclosed
EP-3946604-A1 BENZOPYRANE AND IMIDAZOLE DERIVATIVES USEFUL FOR THE STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS The Scripps Research Institute (US) 2022-02-09 EP disclosed
CN-113396153-A Amino acid salts of nicotinic acid mononucleotide and nicotinamide mononucleotide as anti-aging agents 江普斯塔特生育有限公司 2021-09-14 CN disclosed
EP-2699557-B1 3-(OXAZOL-2-YL-ETHOXY)- AND 3-(THIAZOL-2-YL-ETHOXY)-BENZAMIDE DERIVATIVES AS ANTI-BACTERIAL AGENTS BIOTA SCIENT MANAGEMENT (AU) 2017-08-16 EP disclosed
US-20170079895-A1 PEPTIDE NANOPARTICLES AND USES THEREFOR ANTERIOS, INC. 2017-03-23 US disclosed
US-9486409-B2 Peptide nanoparticles and uses therefor ANTERIOS, INC. (US) 2016-11-08 US disclosed
EP-2944637-A1 NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF FUJIFILM Corporation (JP) 2015-11-18 EP disclosed
US-20150322063-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF FUJIFILM CORPORATION (JP) 2015-11-12 US disclosed
US-20150196490-A1 NANOPARTICLE COMPOSITIONS ANTERIOS, INC. 2015-07-16 US disclosed
US-20140234382-A1 PEPTIDE NANOPARTICLES AND USES THEREFOR ANTERIOS, INC. (US) 2014-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331737-A1 MTORC1 MODULATORS AND USES THEREOF MTOR, RPTOR, RICTOR MAPT 1500/4885RAB9A 462/4885HTT 232/4885
US-20220204485-A1 STABILIZATION OF AMYLOIDOGENIC IMMUNOGLOBULIN LIGHT CHAINS TTR, MAP1LC3B, SAAL1 MAPT 41/4885RAB9A 3384/4885HTT 414/4885
US-20150196490-A1 NANOPARTICLE COMPOSITIONS KRT18, CUTA, HRAS MAPT 406/4885RAB9A 285/4885HTT 736/4885
US-20150322063-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF NPM1, NAP1L1, REN MAPT 3508/4885RAB9A 505/4885HTT 1732/4885
US-20170079895-A1 PEPTIDE NANOPARTICLES AND USES THEREFOR NGLY1, SPPL2B, TFIP11 MAPT 3191/4885RAB9A 3510/4885HTT 1707/4885
US-20140234382-A1 PEPTIDE NANOPARTICLES AND USES THEREFOR NGLY1, SPPL2B, TFIP11 MAPT 3191/4885RAB9A 3510/4885HTT 1707/4885
US-20140135332-A1 AROMATIC AMIDES AND USES THEREOF NAT1, ASNS, CYP2C9 MAPT 2119/4885RAB9A 1391/4885HTT 3614/4885
US-11945806-B2 Stabilization of amyloidogenic immunoglobulin light chains TTR, MAP1LC3B, SAAL1 MAPT 41/4885RAB9A 3384/4885HTT 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.